Oncology product development is changing as the arrival of novel biotherapeutics picks up pace. LINK Medical offers the medical expertise and multidisciplinary knowledge needed to accelerate your time to market.
Biotherapeutics have the potential to provide effective and personalized treatment for patients with unmet clinical need, and they now represent five of the ten most valuable treatments on the market. However, from strict site requirements to complex regulatory frameworks, getting these products to market is not without challenges.
Overcoming obstacles in oncology product development requires experience, broad scientific knowledge and robust strategy at every stage, from early development to commercialization. A strategic partnership with LINK Medical offers the expertise, competence and guidance you need to achieve this. By understanding the unique needs of your business and the regulations, we can assemble a team that can help you develop a strategy for success that will accelerate your time to market.
Our growing multidisciplinary organization includes industry-renowned oncology specialists who can work with you to optimize your clinical development plan and navigate the complex regulatory landscape. Furthermore, with over 2000 oncology products in active clinical trials globally, it is crucial that you carve out a strong business case for your product, and our health economics team uses robust methods to find the value of your product to payers. With further support from our medical affairs and real-world evidence teams, we ensure that you’ll only need ONE source for your entire product development journey.
With active communication and expert knowledge at every step, we will work closely with you to deliver the high-quality documentation that helps you reach the market. Together, we can bring your innovative products to the patients that need them.
Contact us today to find out how LINK Medical offers a strategic partnership through every step of your oncology product development, info@linkmedical.eu or contact us via our form.
For people with the Di.se subscription, find us on page 14:
Risk management in early phase clinical trials – Practical implications